Skip to main content
HRES 280 117th Congress House Foreign Trade and International Finance Administrative law and regulatory procedures Asia China Competition and antitrust Competitiveness, trade promotion, trade deficits Department of Health and Human Services Drug safety, medical device, and laboratory regulation Food and Drug Administration (FDA) Free trade and trade barriers Government information and archives Health technology, devices, supplies Manufacturing Prescription drugs Trade agreements and negotiations

Expressing the sense of the House of Representatives that decades of policies rooted in socialism have stifled United States domestic pharmaceutical drug manufacturing and left the United States exposed to the hostile actions and unfair trade practices of the People's Republic of China.

Introduced: March 26, 2021 Introduced by: Jackson, Ronny Republican · Texas See on congress.gov
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 29, 2021
Referred to the Subcommittee on Health.
Mar 26, 2021
Referred to the Committee on Ways and Means, and in addition to the Committees on Foreign Affairs, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 26, 2021
Referred to the Subcommittee on Trade.
Mar 26, 2021
Introduced in House
 Plain-English summary Congressional Research Service

This resolution commits to the use of competitive free market and free trade policies to combat national security threats caused by China and its attacks on the U.S. pharmaceutical manufacturing base.

The resolution urges the United States to (1) remove tax, regulatory, and debt burdens and barriers that have weakened this base; (2) empower the U.S. Trade Representative to take specified actions to counter harmful and unfair trade practices by China; (3) address shortcomings in Food and Drug Administration data collection related to foreign-sourced pharmaceutical ingredients; and (4) identify and streamline regulatory hurdles that have impeded the U.S. pharmaceutical manufacturing base.

What's happening now March 29, 2021

Referred to the Subcommittee on Health.

 Committees of jurisdiction 5